v3.26.1
Business, Liquidity and Basis of Presentation (Narrative) (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Jan. 15, 2026
May 07, 2026
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Product Information [Line Items]            
Twelve-month escrow held     $ 7,500   $ 0  
Cash and cash equivalents     34,996 $ 18,488 2,998 $ 40,437
Research and development expenses     11,822 21,522    
Revenue     33,736 24,066    
Accumulated deficit     2,143,539   $ 2,182,765  
Pre-Commercial Product Revenue [Member]            
Product Information [Line Items]            
Revenue     4,591 $ 0    
Pre-Commercial Product Revenue [Member] | NPPs [Member]            
Product Information [Line Items]            
Revenue     4,600      
CDMOs and CROs [Member]            
Product Information [Line Items]            
Research and development expenses paid during the period     18,000      
At the Market Offerings [Member] | Subsequent Event [Member]            
Product Information [Line Items]            
Proceeds from sale of common stock   $ 11,700        
Purchased Assets | Purchase Agreement            
Product Information [Line Items]            
Consideration received under Asset Purchase Agreement and Securities Purchase Agreement $ 111,300          
MiNK Therapeutics, Inc.            
Product Information [Line Items]            
Receipt of payment of related party note receivable     5,200      
Zydus Lifesciences Ltd | Zydus Agreements [Member]            
Product Information [Line Items]            
Cash consideration received 91,000   91,000      
Transaction expenses 5,800   5,800      
Twelve-month escrow held 7,500   $ 7,500      
Zydus Lifesciences Ltd | Securities Purchase Agreement            
Product Information [Line Items]            
Cash consideration received 7,200          
Zydus Lifesciences Ltd | Purchased Assets | Zydus Agreements [Member]            
Product Information [Line Items]            
Cash consideration received $ 71,400